Stock Ratings / Health Care / MEDP / financials

CRL (63) ICLR (71) INCY (84) IQV (64) ⌘ Pro Terminal →

Medpace Holdings Inc. (MEDP) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$652.01 -3.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $649.15

Medpace Holdings Inc. (MEDP) earns a Roarable Rating of B+ (Buy) with 80/100 RQD Confidence. High-quality cash engine (steady margins, 28% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 80/100 (B+) historically ranked in the Top 9% of excess returns over the next 90 days (+8.2% avg 90D alpha vs SPY • 71.3% hit rate) →

ROARABLE B+ • BUY Cap $18.95B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MEDP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MEDP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Medpace Holdings Inc. (NASDAQ: MEDP) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 80/100 at a spot price of $652.01 (-3.77% 1D, market cap $18.95B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, MEDP ranks #17 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MEDP compare to CRL and ICLR in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), MEDP carries a Roarable B+ (80/100 RQD), trailing P/E of 42.0x, gross margin of —, and ROIC of 27.9%. By comparison, CRL (Charles River Laboratories International Inc.) holds a C grade (63/100 RQD, P/E N/A, ROIC 0.4%, cap $17.95B) and ICLR (ICON plc) posts a B- grade (71/100 RQD, P/E 71.9x, ROIC 3.1%, cap $16.50B). Among the 5-stock peer group, INCY leads on earnings multiple (18.4x) while INCY leads on capital efficiency (42.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MEDP?

▼

Per MEDP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001668397), Medpace Holdings Inc. generated $2.53B in revenue (+20.0% YoY), $451.1M in net income, and $681.9M in free cash flow against $1.98B in total assets and $682.4M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 42x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $649.14 (-0.44%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 19/20 (A+) • 26.9% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 80/100 (B+) historically ranked in the Top 9% of excess returns over the next 90 days (+8.2% avg 90D alpha vs SPY • 71.3% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw A · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE+9.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MEDP)Realized 20D OHLCV Swing Band: ±7.1%

Deterministic 5-Pillar Attribution (80/100 Composite)

🔍 WHY MEDP SCORES 80/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+19/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 26.9% FCF Margin ($681.9M FCF) & 52% Gross Margin

▲ #2 Bullish Driver: Whale & Options Positioning+18/20 pts (23% of score)

20D Institutional Volume Accumulation (±7.1% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit11/20 pts (-9 pt drag)

Macro rate sensitivity & RSI-14 (61.2) create a -9 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B$609.89+2.1% Next Q

Q2 (-2Q)

Grade B+$622.43+8.3% Next Q

Q3 (-1Q)

Grade B+$673.79-3.2% Next Q

Current

Grade B+$652.01+8.2% Hist 90D α

Trajectory: B (72) → B+ (80)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the MEDP Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 80/100 (B+) score, MEDP faces multiple-compression risk if 42.0x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 42x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($621.41) or 200D SMA ($530.00) invalidates the momentum regime and cuts Target Base ($716.56) toward Bear Floor ($534.65).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MEDP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MEDP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 80%NO 20%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How MEDP Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$681.9M (26.9% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.89B

FY24

Rev $2.11B

FY25

Rev $2.53B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$2.53B	52%	21.1%	$451.1M	$681.9M	65.6%
FY 2024	$2.11B	52%	21.2%	$404.4M	$572.3M	48.4%
FY 2023	$1.89B	52%	17.9%	$282.8M	$348.5M	4.2%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MEDP)

✓Walkthrough of MEDP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MEDP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +56.35%▲ ASCENDING CHANNEL

2026-11-02O $692.7H $692.7L $652.0C $652.0VOL 250.6K

RES: $699.4SUP: $599.9SMA50: $621.4SMA200: $530.0

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MEDP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MEDP Butterfly Map → + Track MEDP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

31.7%/yr Implied 5Y Growth

vs. +20.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MEDP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MEDP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MEDP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MEDP)

Health Care Rank #17 of 1016 ⚔️ CRL vs MEDP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MEDP vs. CRL, ICLR, INCY, IQV)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Medpace Holdings Inc. (MEDP) ranks #17 by composite RQD confidence (80/100, grade B+) and #72 by equity capitalization ($18.95B). Within this direct 5-issuer industry benchmark cohort, INCY leads on earnings valuation at 18.4x trailing P/E, while INCY leads on capital efficiency and profitability with 42.4% ROIC and 92.8% gross margin. INCY currently holds the highest overall quantitative score in the immediate peer group at 84/100 (A-) compared with MEDP at 80/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MEDP ACTIVE Medpace Holdings Inc.	B+	80/100	42.0x	—	27.9%	-3.77%	$18.95B	Benchmark Subject
CRL Charles River Laboratories International Inc.	C	63/100	—	—	0.4%	-4.44%	$17.95B	/crl-vs-medp →
ICLR ICON plc	B-	71/100	71.9x	—	3.1%	-1.91%	$16.50B	/iclr-vs-medp →
INCY Incyte Corp.	A-	84/100	18.4x	92.8%	42.4%	+3.07%	$23.68B	/incy-vs-medp →
IQV IQVIA Holdings Inc.	C	64/100	33.3x	—	9.4%	-2.81%	$45.33B	/iqv-vs-medp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001668397

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Medpace Holdings Inc. (MEDP) reported GAAP revenue of $2.53B (+20.0% vs. FY2024 revenue of $2.11B , and +34.2% cumulative change since FY2023) , GAAP net income of $451.1M, operating cash flow of $713.2M, and free cash flow of $681.9M (+19.2% YoY). On the balance sheet, MEDP closed FY2025 with $1.98B in total assets against $682.4M in total debt (Altman Z-Score: 9.13, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$2.53B	$451.1M	$713.2M	$681.9M	$1.98B	$682.4M
FY2024 (FY)	2024-12-31	$2.11B	$404.4M	$608.8M	$572.3M	$2.10B	$573.9M
FY2023 (FY)	2023-12-31	$1.89B	$282.8M	$433.4M	$348.5M	$10.42B	$2.44B

3. MEDP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MEDP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MEDP compare to CRL and ICLR in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MEDP?

Where is MEDP trading relative to its 50-day, 200-day, and 52-week technical levels?

MEDP last traded at $652.01 (-3.77% on volume of 219,636 shares), positioning the stock +4.92% above its 50-day simple moving average ($621.41) and +23.02% above its 200-day simple moving average ($530.00). Across its 52-week range of $373.00 to $693.97, MEDP sits at the 86.9% percentile with a 14-day RSI of 61.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.1% ($605.72 to $698.30).

MEDP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Medpace Holdings Inc. (MEDP)?

In FY 2025 (10-K), MEDP converted $2.5B of revenue into a 52% gross margin, 21.1% operating margin, and $681.9M in free cash flow (26.9% FCF margin).

Direct Sub-Reports: MEDP RQD Cockpit MEDP 12M Forecast MEDP Earnings & Move MEDP Dividends & DRIP MEDP Insiders & 13F MEDP Whale Options MEDP Profit Sankey MEDP News & Why

Sector Peer Dials

Compare →

CRL C

Charles River Laboratories International Inc.

MEDP Core Snapshot

Market Cap $18.95B

Trailing / Fwd P/E 42.0x / 35.3x

Gross Profit Margin —

Return on Capital (ROIC) 27.9%

Free Cash Flow Yield 3.60%

12M Base Price Target $716.56

FREE TRADER TOOLS

Own MEDP Alongside Other Stocks? Run a 30-Second Crash X-Ray

Drop 3–5 tickers into our live Portfolio X-Ray to spot hidden accounting time-bombs and see your composite RQD dial.

⚡ X-Ray My Portfolio With MEDP → 🏆 Trade MEDP in $100K Prop Arena →

MEDP Wire

Why It Moved →

Direct Company Event Yahoo! Finance Canada • 6h ago

Medpace Holdings, Inc. (MEDP) Stock Price, News, Quote & History

Direct Company Event Investor's Business Daily • 9h ago

Medpace Slumps On Solid Report — Where Are The 'Holes?'

Direct Company Event Benzinga • 12h ago

Here’s How Much You Would Have Made Owning Medpace Holdings Stock In The Last 10 Years

Direct Company Event Seeking Alpha • 15h ago

Medpace: Strong Execution Faces A High-Growth Bar (NASDAQ:MEDP)

Direct Company Event Yahoo Finance UK • 18h ago

Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors

ROARABLE RATING BRIEF • RQD 80/100 (B+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MEDP — Medpace Holdings Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:13:53Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, MEDP scores 80 out of 100 with a letter grade of B+, labeled "Roarable Buy — Very Good Cash & Smart-Money Inflow." The composite is built from five pillars. The fundamental cash engine scores 19 of 20, anchored by an ROIC of 27.9% and an FCF yield of 3.6%; for an investor, this pillar is the strongest signal that the business converts capital into cash efficiently, though the 3.6% FCF yield indicates that the market is pricing the stock at a premium to current cash generation. Whale 13F flow scores 18 of 20 on institutional accumulation and options positioning, pointing to sustained interest from large holders; the source does not itemize which institutions or contracts drive that score. Insider conviction scores 16 of 20 on SEC Form 4 and Congressional PTR cluster flow, suggesting insiders and certain officials have been net buyers, though the magnitude of those trades is not detailed in the source. Macro regime fit is the weakest pillar at 11 of 20, reflecting a beta of 1 and the sector sensitivity noted in the rating; an investor should expect the stock to move roughly in line with the broad market, with less insulation from a sector-level downturn. The forensic balance sheet scores 16 of 20, supported by an Altman Z-Score of 9.13, a Piotroski F-Score of 7 out of 9, and a Debt/Equity ratio of 1.39. The valuation tradeoff is clear from the market data: a trailing P/E of 42 and forward P/E of 35.3 imply that upside depends on sustained earnings growth rather than on current multiples. A prospective investor should weigh the strong cash and balance-sheet metrics against the elevated valuation and the sector-sensitive macro profile.

Snapshot

Metric	Value
Price	$677.56
Market Cap	$18.95B
P/E (TTM)	42
Forward P/E	35.3
EV/EBITDA	34
EPS (TTM)	16.13
Dividend Yield	0%
Beta	1
52-Wk Range	$373 – $693.97
ROIC %	27.9%

Business

Medpace Holdings Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Commercial Physical & Biological Research industry, per the company profile. The profile does not describe its specific products, customer base, or revenue model. Source data does not state to whom the company sells or how it generates revenue beyond the reported financial lines. Market capitalization is listed at $19.0B.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$2530.2M	$534.9M	$451.1M	N/A	$681.9M	$497.0M	$682.4M
FY 2024	$2109.1M	$446.9M	$404.4M	N/A	$572.3M	$669.4M	$573.9M
FY 2023	$1885.8M	$336.8M	$282.8M	N/A	$348.5M	N/A	$2439.2M

Per the SEC financials, revenue grew from $1885.8M in FY 2023 to $2530.2M in FY 2025, and operating income rose from $336.8M to $534.9M over the same span. Per the market data, the operating margin is 21.1% and the net margin is 17.8%; the gross margin is reported as 0%, which the source does not explain. Per the Roarable RQD rating, ROIC is 27.9%. The Altman Z-Score is 9.13 and the Piotroski F-Score is 7 out of 9, both per the Roarable RQD rating. Debt was $682.4M at FY 2025 against cash of $497.0M, and the Debt/Equity ratio is 1.39 per the rating.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, six items are tagged for MEDP. One is flagged GREEN as a CATALYST: a Seeking Alpha piece headlined that the company's strong execution "faces a high-growth bar." One is flagged RED as RISK WATCH: an Investor's Business Daily report headlined that the stock "slumps on solid report." Four are YELLOW market-wire items, including a TradingView report stating the company's Q3 2026 results were in line with expectations, and a Yahoo Finance UK item noting the stock declined while the market improved. The feed also includes a Benzinga 10-year return piece. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals, so no cross-company catalyst can be drawn from it. The news items are headlines and summaries only; the source does not provide their full text or quantified impact.

Analyst View & Smart Money Ownership

Analyst data is not available in source data. No consensus rating or price targets are provided.

Holder data is not available in source data. No SEC Form 4 insider, 13F institutional, or Congressional trade detail is itemized in the holders section. The RQD rating references insider and institutional flow in aggregate, but the underlying trades are not provided.

Open Questions

What is the composition of the reported 0% gross margin, given that operating and net margins are positive?
Which institutions and which insider or Congressional trades drive the whale-flow and insider-conviction pillar scores?
What were the EPS figures for FY 2023 through FY 2025, which are listed as N/A in the filings?
What drove the FY 2023 debt of $2439.2M and why is cash not reported for that year?
What is the full text and quantified impact behind the RED-flagged RISK WATCH headline on the stock's post-report decline?

MEDP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Medpace Holdings Inc. (MEDP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MEDP Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo! Finance Canada • 6h ago

Medpace Holdings, Inc. (MEDP) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Investor's Business Daily • 9h ago

Medpace Slumps On Solid Report — Where Are The 'Holes?'

Investor's Business Daily report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 12h ago

Here’s How Much You Would Have Made Owning Medpace Holdings Stock In The Last 10 Years

Benzinga report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 15h ago

Medpace: Strong Execution Faces A High-Growth Bar (NASDAQ:MEDP)

Seeking Alpha report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance UK • 18h ago

Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors

Yahoo Finance UK report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 21h ago

Medpace (NASDAQ:MEDP) reports Q3 2026 in line with expectations

TradingView report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 1d ago

Medpace: A Shorter, Cleaner Backlog Is Being Mistaken For A Smaller One (NASDAQ:MEDP)

Seeking Alpha report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 1d ago

What To Expect From Medpace’s (MEDP) Q3 Earnings

Yahoo Finance report covering Medpace Holdings Inc. (MEDP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MEDP Bull vs. Bear Conversation Board — What's Your Call at $652.01?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MEDP 🐻 33% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $799.52 (+18.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MEDP (B+ • RQD 80/100) a Buy at $677.56?

Welcome to the MEDP (Medpace Holdings Inc.) Roar Pit. Current RQD Composite is 80/100 (Roarable Buy — Very Good Cash & Smart-Money Inflow) in Biotechnology: Commercial Physical & Biological Resarch. Bulls point to capital efficiency (27.9% ROIC), while bears focus on valuation multiple compression (42.0x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $535.27 (-21.0%)

Spot @ $677.56

Pump the brakes on MEDP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MEDP, but look at what you are paying: 42.0x trailing P/E with tightening sector spreads. Unless Medpace Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $772.42 (+14.0%)

Spot @ $677.56

MEDP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MEDP, the market is fixating on short-term headline noise in Biotechnology: Commercial Physical & Biological Resarch and ignoring the balance sheet and cash flow trajectory. At $677.56 (52-wk range $373.00 - $693.97), any beat on forward guidance forces shorts and underweight funds to chase.